REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm
Disclosure Under Scrutiny: Replimune's SEC filings warned generally that RP1 might not win approval, yet allegedly omitted that the FDA had already told the Company its study design concerns were unresolved. NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors...